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he scientiﬁ  c strategic plan of 
the Global HIV/AIDS Vaccine 
Enterprise, published in this 
month’s PLoS Medicine, is a clear and 
cogent document describing how 
major funders and stakeholders in 
HIV vaccine development should 
move forward in a collaborative 
fashion [1]. There is no doubt that 
this roadmap will be regarded as a 
useful instrument to bring greater 
cohesion and coordination to the 
ﬁ  eld. The individuals who championed 
this effort should be commended 
for providing a great service to the 
scientiﬁ  c community. It is an excellent 
start to a continuing dialogue of utmost 
importance.
The Challenge
Why is it that we still do not have a 
protective vaccine against HIV 22 years 
after its initial identiﬁ  cation? Many 
possible explanations come to mind. 
In the natural course of HIV 
infection, the virus wins 99% of the 
time, showing that speciﬁ  c immunity 
in an infected person is unable to 
completely clear the virus. We have also 
known for over a decade that primary 
HIV isolates are relatively resistant 
to antibody neutralization, probably 
because of a “protective shield” on 
the viral envelope glycoproteins, 
consisting of variable loop sequences 
and extensive N-linked glycosylations. 
Another explanation is the extreme 
plasticity of HIV that allows new viral 
variants to evade immune recognition 
in the same way that they escape 
from drugs. Moreover, superinfection 
by a second viral strain has been 
documented in a number of individuals 
who have already mounted immune 
responses to the initial HIV infection. 
Yet another problem is that the AIDS 
research community has yet to uncover 
the correlates of immune protection in 
vivo. Lastly, proven vaccine approaches 
from the past have either failed (whole 
killed virus and subunit vaccines) 
or faced seemingly 
insurmountable 
regulatory hurdles (live 
attenuated virus vaccine). 
Given these daunting 
obstacles, why have so 
many continued in the 
long struggle to develop 
an HIV vaccine? The 
answer must lie, in part, 
in the noble cause at 
hand. Yet there are 
also some encouraging 
clinical and experimental 
observations (Figure 
1). Rare patients do 
control HIV infection 
spontaneously. Certain 
people remain virus-
negative despite 
repeated exposures. 
That superinfection is 
not more commonly 
found supports the notion of immune 
control. Vaccine-mediated protection 
against simian immunodeﬁ  ciency virus 
is indeed possible using live viruses 
attenuated by speciﬁ  c mutations or 
by pharmacological interventions. 
Finally, and perhaps most importantly, 
HIV transmission by sex in the natural 
setting is typically inefﬁ  cient (and 
thus easier to block), unlike most 
experimental challenge systems 
employed in monkey studies to date. 
Collectively, these ﬁ  ndings provide a 
ray of hope to push on.
The Enterprise 
The scientiﬁ  c strategic plan of the 
Enterprise is spot-on in identifying 
the major roadblocks in HIV vaccine 
development, as well as in establishing 
the key scientiﬁ  c priorities as we see 
them today [1]. It rightly recommends 
the formation of a growing alliance 
of organizations to foster a better 
collaborative spirit that could lead to, 
among other things, stronger political 
support and increased funding. The 
proposed greater coordination and 
management, sharing of information, 
technologies, and reagents, and 
harmonization of standards, assays, 
and approaches could only add to our 
overall efforts. 
One might ask, however, whether 
there are potential downsides to the 
plan. In the name of continuing this 
important dialogue, I would like to 
offer one general concern. Arguably, 
the reason for the lack of an effective 
HIV vaccine today is rooted in the 
basic problems posed by the virus 
itself. What we need foremost are 
new scientiﬁ  c solutions, although 
a prim and proper “process and 
structure” in our approach will be 
helpful. The needed breakthroughs 
to develop a vaccine will likely emerge 
from the creativity of scientists 
doing fundamental research that is 
free of preconceived biases. It is my 
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Figure 1. Rays of Hope: Clinical and Experimental Observations 
Suggesting That an HIV Vaccine Is Feasible
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contention that great new ideas are as 
likely to come from curiosity-driven 
basic studies as from the mission-
oriented approach that is represented 
by the new proposal. Therefore, 
the leadership of the Enterprise 
must safeguard against the kind of 
“group think” that is so pervasive in 
large collaborative endeavors of this 
nature. The views of a small number 
of researchers, no matter how smart 
or accomplished, must not supersede 
the collective wisdom of the scientiﬁ  c 
community at large. 
No doubt important contributions 
will be made by scientists working 
outside of the Enterprise. Measures 
should be taken to ensure that their 
views and approaches, even if deemed 
unconventional, are not stiﬂ  ed by the 
newly established system. Likewise, 
their research support should not be 
compromised because the creation 
of the Enterprise concentrates the 
funding into the hands of a relatively 
small number of designated scientists. 
To me this is a serious risk given the 
current “ﬂ  at funding” at the National 
Institutes of Health. 
The Future
The authors of the “The Global HIV/
AIDS Vaccine Enterprise: Scientiﬁ  c 
Strategic Plan” have laid out a timely 
and insightful plan to address perhaps 
the greatest public-health need of 
the millennium. This document and 
its later revisions will serve as useful 
guideposts for the AIDS vaccine 
development effort for years to come. 
To be successful in this mission, our 
research community will ultimately 
need a speciﬁ  c “scientiﬁ  c blueprint” 
for making an HIV vaccine. That day 
will come only after we get another 
shot in the arm, infusing us with new 
knowledge and know-how. Is there any 
doubt that we need to redouble our 
investment in basic research on the 
challenges posed by HIV?  
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